TriangleACR-368 (NCT05548296)
ACR-368 trial for Endometrial Adenocarcinoma (NCT05548296). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with progressing metastatic endometrial cancer after platinum chemotherapy and PD-1/PD-L1 treatment. Histology and prior-line limits differ by group.
The idea: ACR-368 blocks CHK1, disrupting DNA repair. Biomarker-positive patients receive it alone. Separate serous-cancer groups receive it alone or with ultra-low-dose gemcitabine, intended to increase sensitivity. The biomarker-negative group is closed. New biopsy requirements apply to biomarker selection; unselected groups provide archived tissue. Researchers measure tumor responses.
This phase 2 study plans 350 patients. Acrivon Therapeutics sponsors it; 42 US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.